Mechanism animal study 2014
An animal study reported that the procognitive and synaptogenic effects of angiotensin IV derived peptides depend on activation of the HGF and c-Met system. Reported in the cited paper.
SourceResearch Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →
The directory
83 listed
Newsletter · Quarterly
Get notified about new lab results, price drops and supplier coupons before everyone else.
We respect your privacy. No spam.
Dihexa is a synthetic compound derived from angiotensin IV, developed at Washington State University and studied as a procognitive agent acting through the hepatocyte growth factor and c-Met system. No human clinical trial of dihexa has been published.
Vendor listings
Show prices as
6 listings · Dihexa
In stock10mgseen 6d ago
In stock5mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 5d ago
In stock20mgseen 6d ago
Out of stock10mgseen 3d ago
Overview
Dihexa is a synthetic compound derived from angiotensin IV, developed at Washington State University and studied as a procognitive agent acting through the hepatocyte growth factor and c-Met system. No human clinical trial of dihexa has been published.
What the research reports
Outcomes described across the published Dihexa literature and ongoing study. Read each as research context rather than a promised personal result.
Synaptogenesis animal study
Animal work reports formation of new synaptic connections, which is the mechanism behind the procognitive claims made for this compound. Reported in research settings.
HGF and c-Met pathway work
Acts by activating the hepatocyte growth factor and c-Met receptor system, a pathway tied to neuronal survival and plasticity. Reported in research settings.
High laboratory potency data
Active at very low concentrations in cell based synaptogenesis assays, which is a measure of potency rather than of clinical effect. Reported in research settings.
Memory model animal study
Studied in animal models of impaired cognition, including scopolamine induced amnesia and Alzheimer's disease models. Described in the research record.
Neuroprotection study note
Reviews propose neuroprotective potential through the same growth factor pathway, though no controlled human data supports this. Reported in research settings.
Dosage and protocol
Protocols report 10 to 20 mg orally or 0.5 to 2 mg subcutaneously once daily. No human pharmacokinetic data supports these figures. Figures describe study protocols, not a personal regimen.
Clinical evidence
The published Dihexa record, labeled by strength so you can see what is settled and what is still emerging.
An animal study reported that the procognitive and synaptogenic effects of angiotensin IV derived peptides depend on activation of the HGF and c-Met system. Reported in the cited paper.
SourceAn animal study in 40 rats found that an angiotensin IV analogue did not protect against 3-nitropropionic acid induced Huntington's like symptoms. Reported in the cited paper.
SourceA systematic review of experimental studies examined cognitive effects of angiotensin IV and angiotensin 1-7 across the available animal literature. Reported in the cited paper.
SourceInteractions
Questions